MA53110A - Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton - Google Patents

Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton

Info

Publication number
MA53110A
MA53110A MA053110A MA53110A MA53110A MA 53110 A MA53110 A MA 53110A MA 053110 A MA053110 A MA 053110A MA 53110 A MA53110 A MA 53110A MA 53110 A MA53110 A MA 53110A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitors
polycyclic compounds
bruton tyrosine
bruton
Prior art date
Application number
MA053110A
Other languages
English (en)
Inventor
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53110A publication Critical patent/MA53110A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053110A 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton MA53110A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
MA53110A true MA53110A (fr) 2021-05-12

Family

ID=57681784

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053110A MA53110A (fr) 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA43409A MA43409B1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43409A MA43409B1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Country Status (30)

Country Link
US (5) US10717745B2 (fr)
EP (2) EP3719022A1 (fr)
JP (2) JP6835846B2 (fr)
KR (1) KR102103395B1 (fr)
CN (2) CN108884106A (fr)
AR (1) AR107042A1 (fr)
AU (1) AU2016366541B2 (fr)
BR (1) BR112018011526B1 (fr)
CA (1) CA3007990C (fr)
CY (1) CY1123263T1 (fr)
DK (1) DK3386991T3 (fr)
EA (1) EA035168B1 (fr)
ES (1) ES2805835T3 (fr)
HR (1) HRP20201193T1 (fr)
HU (1) HUE049502T2 (fr)
IL (1) IL259863B (fr)
JO (1) JO3794B1 (fr)
LT (1) LT3386991T (fr)
MA (2) MA53110A (fr)
MD (1) MD3386991T2 (fr)
ME (1) ME03803B (fr)
MX (1) MX387590B (fr)
PL (1) PL3386991T3 (fr)
PT (1) PT3386991T (fr)
RS (1) RS60604B1 (fr)
SI (1) SI3386991T1 (fr)
SM (1) SMT202000404T1 (fr)
TW (1) TWI729047B (fr)
UY (1) UY37015A (fr)
WO (1) WO2017100662A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3596087A1 (fr) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Procédés de formation sélective de liaison aryle- et hétéroaryle-azote
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
EP3953345B1 (fr) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Dérivés de pyridines comme inhibiteurs de malt1
JP7434575B2 (ja) * 2020-01-07 2024-02-20 メッドシャイン ディスカバリー インコーポレイテッド 重水素化チエノピリジン系化合物
BR112023017648A2 (pt) * 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
AU2022284369A1 (en) * 2021-06-04 2024-01-25 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
AU2022305095A1 (en) 2021-06-30 2024-02-15 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
AU2023221549A1 (en) * 2022-02-18 2024-10-03 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors
WO2025262118A1 (fr) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Polythérapie utilisant un inhibiteur de malt1 et un inhibiteur de btk

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (fr) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Inhibiteurs de kinase thiatriazaacénaphthylène-6-carbonirile substitués
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
JP5739334B2 (ja) * 2009-08-26 2015-06-24 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
CA2901510C (fr) 2013-03-15 2022-11-29 Janssen Pharmaceutica Nv Procedes pour preparer les derives d'ibrutinib et leurs intermediaires
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation
WO2018103058A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation

Also Published As

Publication number Publication date
HRP20201193T1 (hr) 2020-11-13
WO2017100662A1 (fr) 2017-06-15
HUE049502T2 (hu) 2020-09-28
CA3007990C (fr) 2024-01-02
JO3794B1 (ar) 2021-01-31
EA201891378A1 (ru) 2018-12-28
AR107042A1 (es) 2018-03-14
IL259863B (en) 2020-06-30
IL259863A (en) 2018-07-31
JP7072690B2 (ja) 2022-05-20
BR112018011526A2 (pt) 2018-11-21
KR102103395B1 (ko) 2020-04-23
US11319329B2 (en) 2022-05-03
ES2805835T3 (es) 2021-02-15
TWI729047B (zh) 2021-06-01
EP3386991B1 (fr) 2020-06-03
US10717745B2 (en) 2020-07-21
EA035168B1 (ru) 2020-05-08
JP2018536686A (ja) 2018-12-13
MX387590B (es) 2025-03-18
US20240383914A1 (en) 2024-11-21
MA43409B1 (fr) 2020-10-28
CY1123263T1 (el) 2021-12-31
US10934310B2 (en) 2021-03-02
EP3386991A1 (fr) 2018-10-17
MD3386991T2 (ro) 2020-11-30
PL3386991T3 (pl) 2021-03-08
US20170283430A1 (en) 2017-10-05
US12065446B2 (en) 2024-08-20
AU2016366541B2 (en) 2021-05-13
AU2016366541A1 (en) 2018-05-31
BR112018011526B1 (pt) 2024-02-27
US20230097422A1 (en) 2023-03-30
LT3386991T (lt) 2020-08-25
EP3719022A1 (fr) 2020-10-07
TW201734021A (zh) 2017-10-01
JP2021073286A (ja) 2021-05-13
KR20180093974A (ko) 2018-08-22
CN108884106A (zh) 2018-11-23
SMT202000404T1 (it) 2020-09-10
RS60604B1 (sr) 2020-08-31
UY37015A (es) 2017-06-30
JP6835846B2 (ja) 2021-02-24
CA3007990A1 (fr) 2017-06-15
NZ742484A (en) 2021-09-24
SI3386991T1 (sl) 2020-08-31
PT3386991T (pt) 2020-08-18
US20190276471A1 (en) 2019-09-12
MX2018007075A (es) 2018-11-09
US20210101910A1 (en) 2021-04-08
ME03803B (fr) 2021-04-20
CN113121562A (zh) 2021-07-16
CN113121562B (zh) 2022-09-13
DK3386991T3 (da) 2020-07-13

Similar Documents

Publication Publication Date Title
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EP2989106A4 (fr) Composés hétérocycliques fusionnés en tant qu'inhibiteurs de protéine kinase
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
ME03334B (fr) Composés hétéroaryle d'inhibition de la kinase
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA50013A (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton